Compression stockings has no

(Australian standard) The timely assessment of VTE risk is very important to determine the need for VTE
prevention. The earlier it is diagnosed the better it will be to start treatment or any other prevention
methods.

Certain risk factors make someone more likely to develop blood clots, Which might includes their
general health and mobility, family history, other health conditions such as cancer, heart disease,
obesity, age over 60, varicose veins with phlebitis. Some medications including over-the-counter and
complementary medicines, such as the oral contraceptive, can make the blood more likely to clot too.

A robust multidisciplinary VTE prevention program should be in place that facilitates an assessment of a
patient’s VTE risk according to evidence-based guidelines, taking all the risk factors into consideration.

Management:

As the management of VTE, mechanical compressions such as compression stockings are being used.
And it was believed that they might reduce the post thrombotic syndrome after DVT. (page 3) However,
trials and Meta analysis have found no evidence supporting this claim. And the mechanical compression
is contraindicated in the patients with following conditions such as Peripheral neuropathy, Peripheral
vascular disease, Leg deformity, Leg oedema, Pulmonary oedema, Dermatitis, Morbid obesity, , Acute
stroke .

And those with diabetes or arteriosclerosis, a comprehensive vascular assessment should be in place to
exclude peripheral arterial disease. (Australian standard page 22)

Anti coagulation and Anti-clotting medicines are administered as a preventative measure, according to
the current guideline. The uses of anti coagulants’ are assessed according to the thrombosis and
bleeding risk. While selecting these medications a different factor has to be considered too. Such as,
kidney and liver function, whether the patient is already taking other medications which could have
effect in bleeding and clotting such as , NSAIDs, Clopidogrel, dipyridamol etc., the presence of any GIT
disorders, possible food and drug interactions, any cultural beliefs, and also dose adherence.

While in hospital, the system to support monitoring and documentation of complications such as
bleeding or thrombosis, or medicine-related problems associated with the use of anticoagulant
medicines has to be in place. Signs and symptoms of VTE related complications should be educated to
the patients and monitored regularly as the clinical conditions and VTE risk are dynamic and change over
time. And reassessment of risk of VTE has to be done at least every 7 days while the patients are in
hospital. (page 23 australian standard)